Biosimilar Interchangeability Requirements Pushed At Inflectra Review
Executive Summary
Celltrion is not seeking interchangeable status, but it had data on a single transition from EU-approved Remicade; however, FDA's advisors said data on multiple switches between products would more accurately reflect real-world clinical practice.
You may also be interested in...
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Draft guidelines on interchangeability and statistical considerations due by end of 2017, suggesting long-awaited documents may not see the light of day this year as many had hoped.